Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Dell Technologies Inc (DELL) Price & Performance

Abeona Therapeutics IncTrade
Dell Technologies IncTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Dell Technologies Inc — how do they compare? Abeona Therapeutics Inc trades at $7.38 (market cap $421.19M), while Dell Technologies Inc trades at $463.5 (market cap $284.93B). The key difference: Dell Technologies Inc is far larger — about 676.5× Abeona Therapeutics Inc's market cap, and Dell Technologies Inc pays a 0.57% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.

ABEODELL
Market Cap
$421.19M$284.93B
Sector
HealthTechnology
52-Week High
$7.45$467.27
52-Week Low
$4.17$111.10
Enterprise Value
$276.10M$304.51B
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.

The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.

Dell Technologies Inc

Dell Technologies stock trades at $457.93, up 0.92% on the day, near its 52-week high. Recent earnings beats, including Q1 2026 EPS of $4.86 versus $2.96 expected, highlight strong operational performance. The technical outlook is bullish with support at $448 and resistance at $471. Revenue for 2025 reached $95.57 billion with net income of $4.59 billion, though cash flow trends show net outflows.

The outlook remains positive driven by AI server demand and commercial PC refresh cycles, with a consensus price target of $503.76 implying 10% upside. Risks include valuation concerns at a P/E of 35.14 and competitive pressures in the tech hardware sector. Institutional sentiment is bullish with 57.78% of analysts rating Buy.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Dell Technologies Inc

VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses

Read more on DELL